Market Cap- 3,613 Cr.
Promoter holding 39.4 %
Stock P/E 48.4
Industry PE 24.9
ROCE 23.7 %
ROE 20.9 %
OPM 19 %
EBIDT growth 3Years 36.5 %
EPS 20.5 vs 19.8 vs 17.1
FII's (Sept 2022 vs June 2022 vs March 2022)
5.76 vs 1.84 vs 2.23
Company is almost debt free.
Company has delivered good profit growth of 43 % CAGR over last 5 years
Company has a good return on equity (ROE) track record: 3 Years ROE 26.5%
Ami Organics Limited is one of the leading research and development-driven manufacturers of specialty chemicals which are primarily chemical components used in fine and agro chemicals. Their key products under the API segment have captured 50-90% of the global market share
With a legacy of 14 years, the Company has developed and commercialized over 450 pharma intermediates across 17 key therapeutic areas since inception and NCE, which are being supplied to over 450 customers in India and 50 countries overseas.
They also have the capacity to manufacture advanced pharmaceutical intermediates and other specialty chemicals on a make-to-order basis. Its R&D team works closely with customers and provides them with cost-efficient and innovative solutions
Some of the regions where Ami Organics has customers are the USA, China, Israel, Japan, Latin America.
The Co.’s client list includes major companies like Laurus Labs Limited, Cadila Healthcare Limited and Cipla Limited, Fabbrica Italiana Sintetici S.p.A, Chori Co. Ltd., Medichem S.A., and many more.
Promoter holding 39.4 %
Stock P/E 48.4
Industry PE 24.9
ROCE 23.7 %
ROE 20.9 %
OPM 19 %
EBIDT growth 3Years 36.5 %
EPS 20.5 vs 19.8 vs 17.1
FII's (Sept 2022 vs June 2022 vs March 2022)
5.76 vs 1.84 vs 2.23
Company is almost debt free.
Company has delivered good profit growth of 43 % CAGR over last 5 years
Company has a good return on equity (ROE) track record: 3 Years ROE 26.5%
Ami Organics Limited is one of the leading research and development-driven manufacturers of specialty chemicals which are primarily chemical components used in fine and agro chemicals. Their key products under the API segment have captured 50-90% of the global market share
With a legacy of 14 years, the Company has developed and commercialized over 450 pharma intermediates across 17 key therapeutic areas since inception and NCE, which are being supplied to over 450 customers in India and 50 countries overseas.
They also have the capacity to manufacture advanced pharmaceutical intermediates and other specialty chemicals on a make-to-order basis. Its R&D team works closely with customers and provides them with cost-efficient and innovative solutions
Some of the regions where Ami Organics has customers are the USA, China, Israel, Japan, Latin America.
The Co.’s client list includes major companies like Laurus Labs Limited, Cadila Healthcare Limited and Cipla Limited, Fabbrica Italiana Sintetici S.p.A, Chori Co. Ltd., Medichem S.A., and many more.
交易开始:
Raise SL to 985
评论:
Target 1 achieved > 7% up
交易结束：到达目标
*DISCLAIMER*
For educational purposes only. Not a recommendation.
Treat StopLoss as your best friend to get you out of troubles.
For educational purposes only. Not a recommendation.
Treat StopLoss as your best friend to get you out of troubles.